The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index; 106 of the 206 sources its claims cite were checked for support.
The current state of the art and future trends in RAS-targeted cancer therapies
Open accessAbstract
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state. Some of these inhibitors have proven efficacy in patients with KRASG12C-mutant cancers and have become practice changing. The excitement associated with these advances has been tempered by drug resistance, which limits the depth and/or duration of responses to these agents. Improvements in our understanding of RAS signalling in cancer cells and in the tumour microenvironment suggest the potential for several novel combination therapies, which are now being explored in clinical trials. Herein, we provide an overview of the RAS pathway and review the development and current status of therapeutic strategies for targeting oncogenic RAS, as well as their potential to improve outcomes in patients with RAS-mutant malignancies. We then discuss challenges presented by resistance mechanisms and strategies by which they could potentially be overcome. The RAS oncogenes are among the most common drivers of tumour development and progression but have historically been considered undruggable. The development of direct KRAS inhibitors has changed this paradigm, although currently clinical use of these novel therapeutics is limited to a select subset of patients, and intrinsic or acquired resistance presents an inevitable challenge to cure. Herein, the authors provide an overview of the RAS pathway in cancer and review the ongoing efforts to develop effective therapeutic strategies for RAS-mutant cancers. They also discuss the current understanding of mechanisms of resistance to direct KRAS inhibitors and strategies by which they might be overcome. Owing to intrinsic and extrinsic factors, KRAS and other RAS isoforms have until recently been impervious to targeting with small-molecule inhibitors. Inhibitors of the KRASG12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer, for which such an agent has been approved by the FDA. Several forms of resistance to KRAS inhibitors have been defined, including primary, adaptive and acquired resistance; these resistance mechanisms are being targeted in studies that combine KRAS inhibitors with inhibitors of horizontal or vertical signalling pathways. Mutant KRAS has important effects on the tumour microenvironment, including the immunological milieu; these effects must be considered to fully understand resistance to KRAS inhibitors and when designing novel treatment strategies. Owing to intrinsic and extrinsic factors, KRAS and other RAS isoforms have until recently been impervious to targeting with small-molecule inhibitors. Inhibitors of the KRASG12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer, for which such an agent has been approved by the FDA. Several forms of resistance to KRAS inhibitors have been defined, including primary, adaptive and acquired resistance; these resistance mechanisms are being targeted in studies that combine KRAS inhibitors with inhibitors of horizontal or vertical signalling pathways. Mutant KRAS has important effects on the tumour microenvironment, including the immunological milieu; these effects must be considered to fully understand resistance to KRAS inhibitors and when designing novel treatment strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
69 Valid · 1 Not valid · 62 Not checked · 20 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“These alterations included secondary KRAS mutations (G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R or Y96C) in nine patients (23%)”
§ The current state of the art and future trends in RAS-targeted cancer therapies > Resistance to KRAS inhibition > Acquired resistance due to mutational escape
What the sources say
- Disputedcites [106] Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021). sourceExperimental — accuracy not yet measured
The Discussion reports acquired KRAS mutations in 7 of the 38 patients, not nine (23%). The paper identifies the listed mutations, but its count contradicts the citing sentence; its separate counts of five patients with codon 12 mutations and four with drug-binding-pocket mutations should not be added as distinct patients. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainn = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
§ The current state of the art and future trends in RAS-targeted cancer therapies > Abstract
What the sources say
- Partly supportedcites [25] Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828–851 (2014). sourceExperimental — accuracy not yet measured
Our copy supports the core of the claim: the section opener 'Direct inhibitors of Ras – druggable after all?' states that 'Direct targeting of Ras has been thought to be a very challenging task, if not downright impossible' because 'there do not appear to be any deep hydrophobic pockets on the surface of K-Ras that would allow tight binding of small molecules', and the synthetic-lethality section calls KRAS 'an undruggable oncogene'. However, the paper locates the pocket deficiency in the K-Ras protein surface generally (shared by wild-type and mutant), not specifically 'within the mutant isoforms' as the citing sentence states; indeed the mutant-specific G12C work (Shokat, Gray) is presented as exploiting a mutation-introduced cysteine and an α2/α3 pocket rather than as overcoming a mutant-specific pocket deficit. The 'long viewed as undruggable' framing and the no-targetable-pockets rationale are supported; the mutant-isoform qualifier is not attributable to this source. (LLM, conf=0.68)
- Not checked yetcites [26] Cox, A. D. & Der, C. J. Ras history: the saga continues. Small GTPases 1, 2–27 (2010). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
§ The current state of the art and future trends in RAS-targeted cancer therapies > Abstract
What the sources say
- Partly supportedcites [65] Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604–608 (2016). sourceExperimental — accuracy not yet measured
The paper’s Abstract reports an allele-specific inhibitor that binds inactive, GDP-bound KRASG12C. It does not report an inhibitor selective for the active, GTP-bound state, so it supports only the inactive-state part of the claim. (LLM, conf=0.88)
- Partly supportedcites [66] Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589 e517 (2018). sourceExperimental — accuracy not yet measured
The Summary and Introduction (page numbers unavailable) describe structure-based design of ARS-1620, a selective KRASG12C inhibitor that targets the inactive, GDP-bound state. The Introduction discusses attempts to target active-state conformations, but does not establish that drug design produced a mutant-selective inhibitor of the active state. (LLM, conf=0.87)
- Partly supportedcites [67] Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021). sourceExperimental — accuracy not yet measured
The passage labeled Abstract > Conclusions (page not provided) says structural and mechanistic advances enabled selective KRASG12C inhibitors and identifies sotorasib as an inhibitor that binds the inactive GDP-bound conformation. It does not describe an inhibitor selective for mutant KRAS in its active state. (LLM, conf=0.86)
- Partly supportedcites [68] Hallin, J. et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). sourceExperimental — accuracy not yet measured
The Introduction (page not specified) describes advances in drug design that produced more potent KRASG12C inhibitors, but says the potent covalent inhibitors described bind only GDP-bound KRAS. The Results (page not specified) likewise show that MRTX849 preferentially binds the inactive, GDP-bound form. Our copy does not support the claim that inhibitors selective for active-state mutant KRAS had also been developed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered ‘undruggable’”
§ The current state of the art and future trends in RAS-targeted cancer therapies > Abstract
What the sources say
- Partly supportedcites [16] Consortium, A. P. G. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017). sourceExperimental — accuracy not yet measured
The “Comparison with TCGA” section reports KRAS mutations in 27% of non–small cell lung cancers and 47% of colorectal cancers. It does not establish that KRAS is the most frequently altered oncogenic protein across solid tumours. (LLM, conf=0.78)
- Could not verifycites [17] Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012). sourceExperimental — accuracy not yet measured
The portal description (section labelled Abstract; page unavailable) explains how it displays genomic alterations, but it does not rank oncogenic proteins across solid tumours. Searches for KRAS, alteration frequency, and ‘undruggable’ found no passage stating the claim. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“abnormalities in components of the RAS pathway, including activating RAS mutations, are common across a diverse range of malignancies”
§ The current state of the art and future trends in RAS-targeted cancer therapies > The RAS pathway
What the sources say
- Not checked yetcites [1] Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779–827 (1987). source
- Supportedcites [3] Gimple, R. C. & Wang, X. RAS: striking at the core of the oncogenic circuitry. Front. Oncol. 9, 965 (2019). source
The ‘Role of RAS Mutations in Different Cancer Types’ section reports alterations in the RTK–RAS pathway in 46% of cancer samples and RAS alterations in 20–30% of human cancers. It describes activating KRAS, NRAS, and HRAS mutations across multiple cancer types, supporting the claim’s breadth. (LLM, conf=0.94)
- Supportedcites [4] Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017). source
The Cancer section describes the widespread prevalence of RAS mutations in human cancer and explains how activating mutations increase RAS activity. It also documents abnormalities in RAS regulators across several malignancies, supporting the claim's breadth. Page numbers are not available in the supplied passages. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
75 more claims · 48 with their cited sources checked
Create a free account to see all 152 claims and to verify the 100 references still open.
- It may state two separate claims as one. 71
- Probably not a substantial claim. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The KRAS gene, one of the most frequently mutated oncogenes in cancer, has long evaded drug targeting efforts due to the absence of effective druggable pockets on its corresponding proteins.69”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The current state of the art and future trends in RAS-targeted cancer therapies > Overcoming KRASG12C inhibitor resistance > Vertical combinations
“The fact that SHP2 acts downstream of RTKs and upstream of SOS1/2 in the RAS signalling pathway makes this GEF an attractive target for preventing adaptive resistance to KRASG12C inhibitors.”
§ The current state of the art and future trends in RAS-targeted cancer therapies > The RAS pathway
“the SOS1-activating non-receptor protein tyrosine phosphatase SHP2”
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
Research works printed but not linked: 3
- Kuang, S. et al. Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC. J. Clin. Oncol. 39, e21127 (2021).
- Li, B. T. et al. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): plasma biomarker analysis of CodeBreaK100. J. Clin. Oncol. 40 (Suppl. 16), Abstr. 102 (2022).
- Lee, J. W., Kim, S., Yang, C. & Burtness, B. Abstract P078: Aurora A kinase inhibition with VIC-1911 overcomes intrinsic and acquired resistance to KRASG12C inhibition in KRAS(G12C)-mutated lung cancer. Mol. Cancer Ther. 20 (Suppl. 12), Abstr. P078 (2021).
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
Metadata
- Authors
- Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K.
- Affiliations
- NYU Langone Health (US)
- Corresponding author
- Wong, Kwok-Kin
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2022-08-26
- Volume
- 19
- Issue
- 10
- Pages
- 637-655
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC9412785
- OpenAlex
- W4293176236
- Semantic Scholar
- fe2a486e46743392db9d53381c1b2b3e1516b9cc
- Cited by
- 549
- References
- 208
- Citations by year
- 2026: 98 · 2025: 185 · 2024: 163 · 2023: 95 · 2022: 8
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS, Ras signaling, KRAS inhibitors, KRAS G12C, drug resistance, combination therapy, tumor microenvironment, oncogenic Ras, solid tumors, resistance mechanisms
- MeSH terms
- Humans, Mutation, Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The current state of the art and future trends in RAS-targeted cancer therapies. https://app.cochat.ai/papers/10.1038/s41571-022-00671-9
- The paper
- Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022). The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00671-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.